Synthesis and preliminary biological evaluations of CC-1065 analogues: Effects of different linkers and terminal amides on biological activity

Journal of Medicinal Chemistry

Volumn 43, Issue 8, 2000, Pages 1541-1549

  Wang, Yuqiang ^a   Yuan, Huiling ^a   Ye, Wenqing ^a   Wright, Susan C ^a   Wang, Hong ^a   Larrick, James W ^a  

^a Panorama Research Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[5 [(5 ACETAMINO 1H BENZOFURAN 2 YLCARBONYL)AMINO] 1H INDOL 2 YL]CARBONYL] 1,2,9,9A TETRAHYDROCYCLOPROPA[C]BENZ[E]INDOL 4 ONE; 3 [(5 ACETAMINO 1H INDOL 2 YL)ACRYLYL] 1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZE[E]INDOLE; 3 [(5 ACETAMINO 1H INDOL 2 YL)CARBONYL 1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOLE; 3 [[5 [(5 ACETAMINO 1H BENZOFURAN 2 YLCARBONYL)AMINO] 1H INDOL 2 YL]CARBONYL] 1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOLE; 3 [[5 [(5 ACETAMINO 1H INDOL 2 YLCARBONYL)AMINO] 1H INDOL 2 YL]CARBONYL] 1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOLE; 3 [[5 [(5 BUTYRAMINO 1H BENZOFURAN 2 YLCARBONYL)AMINO] 1H INDOL 2 YL CARBONYL] 1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOLE; ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; RACHELMYCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; MELANOMA; MOUSE; NONHUMAN; TUMOR CELL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOFURANS; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; INDOLES; LEUCOMYCINS; LEUKOCYTE COUNT; MALE; MICE; NEOPLASM TRANSPLANTATION; PLATELET COUNT; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0034692179     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990514c     Document Type: Article

References (50)

1. Hanka, L. J.; Dietz, A.; Gerpheide, S. A.; Kuentzel, S. L.; Martin, D. G. CC-1065 (NSC-218223), A new antitumor antibiotic. Production, in vitro biological activity, microbiological assays, and taxonomy of the producing microorganisms. J. Antibiot. 1978, 31, 1211-1217.
2. Martin, D. G.; Chidester, C. G.; Duchamp, D. J.; Mizsk, S. A. Structure of CC-1065 (NSC-218223), a new antitumor antibiotic. J. Antibiot. 1980, 33, 902-903.
3. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Kroeger, W. C.; McGovren, J. P.; Mizsk, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. CC-1065 (NSC-218223), a potent new antitumor agent, improved production and isolation, characterization and antitumor activity. J. Antibiot. 1981, 34, 1119-1125.
4. Bhuyan, B. K.; Newell, K. A.; Crampton, S. L.; Von Hoff, D. D. CC-1065 (NSC-218223), a most potent antitumor agent: Kinetics of inhibition of growth, DNA synthesis and cell survival. Cancer Res. 1982, 42, 3532-3537.
5. Ichimura, M.; Muroi, K.; Asano, K.; Kawamoto, I.; Tomita, F.; Morimoto, M.; Nakano, H. DC89-A1, a new antitumor antibiotic from Streptomyces. J. Antibiot. 1988, 41, 1205-1208.
6. Takahashi, I.; Takahashi, K.; Ichimura, M.; Morimoto, M.; Asano, K.; Kawamoto, I.; Tomita, F.; Nakano, H. Duocarmycin A, a new antitumor antibiotic from Streptomyces. J. Antibiot. 1988, 41, 1915-1917.
7. Yasuzawa, T.; Iida, T.; Muroi, K.; Ichimura, M.; Takahashi, K.; Sano, H. Structures of duocarmycins, novel antitumor antibiotics produced by Streptomyces. sp. Chem. Pharm. Bull. 1988, 36, 3720-3731.
8. 2. J. Antibiot. 1989, 42, 1219-1221.
9. Boger, D. L. The duocarmycins: Synthesis and mechanistic studies. Acc. Chem. Res. 1995, 20, 20-21.
10. Swenson, D. H.; Li, L. H.; Hurley, L. H.; Rokem, J. S.; Petzold, G. L.; Dayton, B. D.; Wallace, T. L.; Lin A. H.; Krueger, W. K. Mechanism of interaction of CC-1065 (NSC-218223) with DNA. Cancer Res. 1982, 42, 2021-2020.
11. Hurley, L. H.; Reynolds, V. L.; Swenson, D. H.; Petzold, G. L.; Scahill, T. A. Reaction of the antitumor antibiotics CC-1065 with DNA: Structure of a DNA adduct with DNA sequence specificity. Science 1984, 226, 843-844.
12. Reynolds, V. L.; Molineaux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, L. H. Reaction of antitumor antibiotic CC-1065 with DNA. Location of the site of thermally induced strand breakage and analysis of DNA sequence specificity. Biochemistry 1985, 24, 6220-6237.
13. Chiang, S. Y.; Welch, J.; Rauscher III, F. J.; Beerman, T. A. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry 1994, 33, 7033-7040.
14. McGovren, J. P.; Clarke, G. L.; Pratt, E. A.; DeKoning, T. F. Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J. Antibiot. 1984, 37, 63-70.
15. For reviews, see: (a) Aristoff, P. A. CC-1065 Analogues: Sequence Specific DNA-alkylating Antitumor Agents. Adv. Med. Chem. 1993, 2, 67-110.
16. (b) Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Goldberg, J. A. CC-1065 and the Duocarmycins: Synthetic Studies. Chem. Rev. 1997, 97, 787-820.
17. Warpehoski, M. A.; Gebhard, I.; Kelly, R. C.; Krueger, W. C.; Li, L. H.; McGovren, J. P.; Prairie, M. D.; Wicnienski, N.; Wierenga, W. Stereoelectronic factors influencing the biological activity and DNA interaction of synthetic antitumor agents modeled on CC-1065. J. Med. Chem. 1988, 31, 590-603.
18. 2: CC-1065 functional analogues incorporating the parent 1,2,7,7a-tetrahydrocyclopropa[1,2-c]indol-4-one (CI) left-hand subunit. J. Org. Chem. 1989, 54, 1238-1240.
19. Boger, D. L.; Coleman, R. S.; Invergo, B. J.; Sakya, S. M.; Ishizaki, T.; Munk, S. A.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C. Synthesis and evaluation of aborted and extended CC-1065 functional analogues: (+)- and (-)-CPI-PED-I1, (+)- and (-)-CPI-CDPI1, and (+)- and (-)-CPI-CDPI3. Preparation of key partial structures and definition of an additional function role of the CC-1065 central and right-hand subunits. J. Am. Chem. Soc. 1990, 112, 4623-4632.
20. Hurley, L. H.; Warpehoski, M. A.; Lee, C. H.; McGovren, J. P.; Scahill, T. A.; Kelly, R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, I.; Johnson, P. D.; Bradford, V. S. Sequence specificity of DNA alkylation by the unnatural enantiomer of CC-1065 and its synthetic analogues. J. Am. Chem. Soc. 1990, 112, 4633-4649.
21. 2: Enhanced functional analogues of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-hand subunit. J. Org. Chem. 1990, 55, 5823-5832.
22. 2BI) alkylation subunit: Synthesis and preliminary DNA alkylation studies. J. Am. Chem. Soc. 1992, 114, 9319-9327.
23. Aristoff, P. A.; Johnson, P. D. Synthesis of CBI-PDE-I-dimer, the benzannelated analogue of CC-1065. J. Org. Chem. 1992, 57, 6234-6239.
24. Aristoff, P. A.; Johnson, P. D.; Sun, D.; Hurley, L. H. Synthesis and biochemical evaluation of the CBI-PDE-I-dimer, a benz-annelated analogue of (+)-CC-1065 that also produces delayed toxicity in mice. J. Med. Chem. 1993, 36, 1956-1963.
25. Wang, Y.; Gupta, R.; Huang, L.; Lown, J. W. Synthesis and antitumor activity of CC-1065 functional analogues possessing different electron-withdrawing substituents and leaving groups. J. Med. Chem. 1993, 36, 4172-4182.
26. 1H NMR and restrained molecular dynamics simulation. J. Am. Chem. Soc. 1995, 117, 8917-8925.
27. Boger, D. L.; Yun, W.; Han, N. 1,2,9,9a-Tetrahydrocyclopropa-[c]benz[e]indol-4-one (CBI) analogues of CC-1065 and the duocarmycins: synthesis and evaluation. Bioorg. Med. Chem. 1995, 3, 1429-1453.
28. 1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit. Bioorg. Med. Chem. 1995, 3, 761-775.
29. Wang, Y.; Gupta, R.; Huang, L.; Luo, W.; Lown, J. W. Design, synthesis, cytotoxic properties and preliminary DNA sequencing evaluation of CPI-N-methylpyrrole hybrids. Enhancing effect of a trans double bond linker and role of the terminal amide functionality on cytotoxic potency. Anti-Cancer Drug Des. 1996, 11, 15-34.
30. Boger, D. L.; McKie, J. A.; Cai, H.; Cacciari, B.; Baraldi, P. G. Synthesis and properties of substituted CBI analogues of CC-1065 and the duocarmycins incorporating th e 7-methoxy-12,9,-9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (MCBI) alkylation subunit: magnitude of electronic effects on the functional reactivity. J. Org. Chem. 1996, 61, 1710-1729.
31. Boger, D. L.; Han, N.; Tarby, C. M.; Boyce, C. W.; Cai, H.; Jin, Q.; Kitos, P. A. Synthesis, chemical properties, and preliminary evaluation of substituted CBI analogues of CC-1065 and the duocarmycins incorporating the 7-cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one alkylation subunit: Hammett quantitation of the magnitude of electronic effects on functional reactivity. J. Org. Chem. 1996, 61, 4894-4912.
32. Lown, J. W.; Wang, Y.; Luo, W. Cyclopropylpyrroloindole-Oligopeptide Anticancer Agents. U.S. Patent US 5,502,068. March 1996.
33. Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spalluto, G.; Gambari, R.; Bianchi, N.; Passadore, M.; Ambrosino, P.; Mongelli, N.; Cozzi, P.; Geroni, C. Synthesis, cytotoxicity, antitumor activity and sequence selective binding of two pyrazole analogues structurally related to the antitumor agents U-71, 184 and adozelesin. Anti-Cancer Drug Des. 1997, 12, 555-576.
34. Boger, D. L.; Garbaccio, R. M.; Jin, Q. Synthesis and evaluation of CC-1065 and duocarmycin analogues incorporating the iso-CI and Iso-CBI alkylation subunit: impact of relocation of the C-4 carbonyl. J. Org. Chem. 1997, 62, 8875-8891.
35. Baraldi, P. G.; Cacciari, B.; Guiotto, A.; Romagnoli, R.; Spalluto, G.; Zaid, A. N. Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogues of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity. Farmaco 1997, 52, 711-716.
36. Baraldi, P. G.; Cacciari, B.; Guiotto, A.; Romagnoli, R.; Spalluto, G.; Zaid, A. N.; Capolongo, L.; Cozzi, P.; Geroni, C.; Mongelli, N. Synthesis, solvolytic stability and cytotoxicity of a modified derivative of CpzI, a pyrazole analogue of the alkylation subunit of the antitumor agent CC-1065: effect of the nitrogen substitution on the functional reactivity. Farmaco 1997, 52, 717-723.
37. Wang, Y.; Wright, S. C.; Larrick, J. W. DNA-binding indole derivatives, their prodrugs and immunoconjugates. U.S. Patent US 5,843,937, December 1998.
38. Boger, D. L.; Santillán, A., Jr.; Searcey, M.; Jin, Q. Critical role of the linking amide in CC-1065 and the duocarmycins: implications on the source of DNA alkylation catalysis. J. Am. Chem. Soc. 1998, 120, 11554-11557.
39. Fukuda, Y.; Seta, S.; Furuta, H.; Ebisu, H.; Oomori, Y.; Terashima, S. The novel cyclopropapyrroloindole (CPI) bis-alkylators bearing 3,3′-(1,4-phenylene)diacryloyl group as a linker. Bioorg. Med. Chem. Lett. 1998, 8, 2003-2004.
40. Boger, D. L.; Turnbull, P. Synthesis and evaluation of a carbocyclic analogue of the CC-1065 and duocarmycin alkylation subunit: Role of the vinylogous amide and implications on DNA alkylation catalysis. J. Org. Chem. 1998, 63, 8004-8011.
41. Boger, D. L.; Santillán, A., Jr.; Searcey, M.; Jin, Q. Synthesis and evaluation of duocarmycin and CC-1065 analogues containing modifications in the subunit linking amide. J. Org. Chem. 1999, 64, 5241-5244.
42. Milbank, J. B. J.; Tercel, M.; Atwell, G. J.; Wilson, W. R.; Hogg, A.; Denny, W. A. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. J. Med. Chem. 1999, 42, 649-658.
43. NCI clinical trials database, 1998.
44. Boyd, M. R. Status of the NCI preclinical antitumor drug discovery screen. Principles Practices Oncol. 1989, 3, 1-12.
45. Kaufmann, S. H. Induction of endonucleolytic DNA clevage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res. 1989, 49, 5870-5878.
46. Barry, M. A.; Behnke, C. A.; Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 1990, 40, 2353-2362.
47. Wrasidlo, W.; Johnson, D. S.; Boger, D. L. Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins. Bioorg. Med. Chem. 1994, 4, 631-636.
48. Wright, S. C.; Schellenberger, U.; Wang, H.; Wang, Y.; Kinder, D. H. Chemotherapeutic drug activation of the AP24 protease in apoptosis: Requirement for caspase 3-like proteases. Biochem. Biophys. Res. Commun. 1998, 245, 797-803.
49. Wright, S. C.; Wei, Q. S.; Zhong, J.; Zheng, H.; Kinder, D. H.; Larrick, J. W. Purification of a 24-kD protease from apoptotic tumors that activated DNA fragmentation. J. Exp. Med. 1994, 180, 2113-2123.
50. Wright, S. C.; Schellenberger, U.; Wang, H.; Kinder, D. H.; Talhouk, J. W.; Larrick, J. W. Activation of CPP32-like proteases is not sufficient to trigger apoptosis: Inhibition of apoptosis by agents that suppress activation of AP24 but not CPP32-like activity. J. Exp. Med. 1997, 186, 1107-1117.